

FORM 26. Docketing Statement**UNITED STATES COURT OF APPEALS
FOR THE FEDERAL CIRCUIT****No. 2014-1294**Purdue Pharma L.P.

v.Epic Pharma, LLC
_____**DOCKETING STATEMENT**

This Docketing Statement must be completed by all counsel and filed with the court within 14 days of the date of docketing. When the United States or its officer or agency is a party, this Docketing Statement must be completed by all counsel and filed with the court within 30 days of docketing. All questions must be answered or the statement will be rejected.

Name of the party you represent **Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue**
Pharmaceuticals L.P., Rhodes Technologies

Party is (select one) Appellant/Petitioner Cross-Appellant
 Appellee/Respondent Intervenor

Tribunal appealed from and Case No. **S.D.N.Y. 13-cv-00683-SHS**

Date of Judgment/Order **January 29, 2014** Type of Case **Patent Infringement**

Relief sought on appeal **Reversal and/or remand**

Relief awarded below (if damages, specify) _____
Denial of Plaintiffs' requests for relief

Briefly describe the judgment/order appealed from _____
Action for patent infringement arising under Hatch-Waxman Act, relating to three patents covering a
greatly reduced level of a particular impurity in the active ingredient in Purdue's OxyContin® tablets.
Judgment of invalidity based on collateral estoppel from a related case, which is the subject of Appeal
Nos. 14-1311, -1312, -1313, and -1314.

FORM 26. Docketing Statement (continued)

Nature of judgment (select one)

Final Judgment, 28 USC 1295

Rule 54(b)

Interlocutory Order (specify type) _____

Other (explain; *see* Fed. Cir. R. 28(a)(5)) _____

Name and docket number of any related cases pending before this court plus the name of the writing judge if an opinion was issued

Purdue Pharma L.P. v. Mylan Pharmaceuticals Inc. (Appeal No. 14-1296)

Purdue Pharma L.P. v. Amneal Pharmaceuticals, LLC (Appeal Nos. 14-1306, -1307)

Grunenthal GmbH v. Teva Pharmaceuticals USA, Inc. (Appeal Nos. 14-1311, -1312, -1313, -1314)

Brief statement of the issues to be raised on appeal _____
The issues are obviousness and claim construction.

Have there been discussions with other parties relating to settlement of this case?

Yes No

If "yes," when were the last such discussions?

Before the case was filed below?

During the pendency of the case below?

Following the judgment/order appealed from?

If "yes," were the settlement discussions mediated? Yes No

If they were mediated, by whom? _____

FORM 26. Docketing Statement (continued)

Do you believe that this case may be amenable to mediation? Yes No

If you answered no, explain why not _____

Purdue does not believe that the involvement of a mediator would materially impact the prospects for settlement.

Provide any other information relevant to the inclusion of this case in the court's mediation program. _____

I certify that I filed an original and one copy of this Docketing Statement with the Clerk of the United States Court of Appeals for the Federal Circuit and served a copy on counsel of record, this 5th day of March, 2014

by: CM/ECF
(manner of service)

Robert J. Goldman

/s/ Robert J. Goldman

Name of Counsel

Signature of Counsel

Law Firm Ropes & Gray LLP

Address 1900 University Avenue, 6th Floor

City, State, ZIP East Palo Alto, CA 94303

Telephone Number (650) 617-4000

FAX Number (650) 566-4150

E-mail Address robert.goldman@ropesgray.com

CERTIFICATE OF SERVICE

On March 5, 2014, the undersigned caused electronic copies of the foregoing document to be sent to the following:

Thomas J. Vetter
LUCAS & MERCANTI, LLP
475 Park Avenue South, 15th Floor
New York, NY 10016
tvetter@lmiplaw.com

Attorney for Defendant/Appellee
Epic Pharma, LLC

/s/ Kerstyn Crumb
Kerstyn Crumb
ROPES & GRAY LLP
1900 University Avenue, 6th Floor
East Palo Alto, CA 94303
(650) 617-4000
kerstyn.crumb@ropesgray.com